Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Harrison Seth Loring 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE 3. Date of Earliest Transaction (Month/Day/Year) 07/16/2026 (Street) BEDFORD, MA 01730 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.8	07/16/2026		G(1)			29,555	(2)	09/09/2029	Common Stock	29,555	$ 0	0	D
Stock Option (Right to Buy)	$28.8	07/16/2026		G(1)		29,555		(2)	09/09/2029	Common Stock	29,555	$ 0	29,555	I	By Trust(3)
Stock Option (Right to Buy)	$26.53	07/16/2026		G(1)			14,777	(4)	06/02/2030	Common Stock	14,777	$ 0	0	D
Stock Option (Right to Buy)	$26.53	07/16/2026		G(1)		14,777		(4)	06/02/2030	Common Stock	14,777	$ 0	14,777	I	By Trust(3)
Stock Option (Right to Buy)	$40.37	07/16/2026		G(1)			11,650	(5)	06/07/2031	Common Stock	11,650	$ 0	0	D
Stock Option (Right to Buy)	$40.37	07/16/2026		G(1)		11,650		(5)	06/07/2031	Common Stock	11,650	$ 0	11,650	I	By Trust(3)
Stock Option (Right to Buy)	$12.96	07/16/2026		G(1)			21,000	(6)	06/06/2032	Common Stock	21,000	$ 0	0	D
Stock Option (Right to Buy)	$12.96	07/16/2026		G(1)		21,000		(6)	06/06/2032	Common Stock	21,000	$ 0	21,000	I	By Trust(3)
Stock Option (Right to Buy)	$12.46	07/16/2026		G(1)			19,441	(7)	06/12/2033	Common Stock	19,441	$ 0	0	D
Stock Option (Right to Buy)	$12.46	07/16/2026		G(1)		19,441		(7)	06/12/2033	Common Stock	19,441	$ 0	19,441	I	By Trust(3)
Stock Option (Right to Buy)	$16.41	07/16/2026		G(1)			7,639	(8)	06/04/2034	Common Stock	7,639	$ 0	0	D
Stock Option (Right to Buy)	$16.41	07/16/2026		G(1)		7,639		(8)	06/04/2034	Common Stock	7,639	$ 0	7,639	I	By Trust(3)
Stock Option (Right to Buy)	$10.9	07/16/2026		G(1)			29,747	(9)	06/02/2035	Common Stock	29,747	$ 0	0	D
Stock Option (Right to Buy)	$10.9	07/16/2026		G(1)		29,747		(9)	06/02/2035	Common Stock	29,747	$ 0	29,747	I	By Trust(3)
Stock Option (Right to Buy)	$29.46	07/16/2026		G(1)			17,786	(10)	06/02/2036	Common Stock	17,786	$ 0	0	D
Stock Option (Right to Buy)	$29.46	07/16/2026		G(1)		17,786		(10)	06/02/2036	Common Stock	17,786	$ 0	17,786	I	By Trust(3)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Harrison Seth Loring C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD, MA 01730	X

Signatures

/s/ Jonathan Allan, Attorney-in-Fact		07/17/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
(2)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
(3)	The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
(4)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
(5)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
(6)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
(7)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
(8)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
(9)	This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.
(10)	The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.